Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2

References

• He X, Zhang C, Shi C, et al. Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers. Oncol Rep. 2018;39:929–938.
   PubMed Web of Science ®Google Scholar
• Chen Y, Mao B, Peng X, et al. A comparative study of genetic profiles of key oncogenesis-related genes between primary lesions and matched lymph nodes metastasis in lung cancer. J Cancer. 2019;10:1642–1650.
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. 2020;38:753–766.
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang LL, Chen JH, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.
   PubMed Web of Science ®Google Scholar
• Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e314S–e340S.
   PubMed Web of Science ®Google Scholar
• Lei Y, Guo W, Chen B, et al. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer. Oncol Rep. 2018;40:3438–3446.
   PubMed Web of Science ®Google Scholar
• Jin X, Liu X, Zhang Z, et al. lncRNA CCAT1 acts as a MicroRNA-218 sponge to increase gefitinib resistance in NSCLC by targeting HOXA1. Mol Ther Nucleic Acids. 2020;19:1266–1275.
   PubMedGoogle Scholar
• Kong X, Duan Y, Sang Y, et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. Journal of Cellular Physiology. 2019;234:9105–9117.
   PubMed Web of Science ®Google Scholar
• Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019;39:22.
   PubMed Web of Science ®Google Scholar
• Wang L, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer, 20. Int J Mol Sci. 2019.
   Web of Science ®Google Scholar
• Shu D, Xu Y, Chen W. Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. J Drug Target. 2020;28:300–306.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu Y, Yang M, et al. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway. BMC Pulm Med. 2020;20:266.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang H, Wang Q, et al. Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC. Minerva Med. 2019;110:273–275.
   PubMed Web of Science ®Google Scholar
• Huang W, Su G, Huang X, et al. Long noncoding RNA PCAT6 inhibits colon cancer cell apoptosis by regulating anti-apoptotic protein ARC expression via EZH2. Cell Cycle. 2019;18:69–83.
   PubMed Web of Science ®Google Scholar
• Dong F, Ruan S, Wang J, et al. M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2. Cell Death Dis. 2020;11:728.
   PubMed Web of Science ®Google Scholar
• Zhang D, Du D, Yi S, et al. LncRNA PCAT6: a potential biomarker for diagnosis and prognosis of bladder cancer. Ann Diagn Pathol. 2020;49:151642.
   PubMed Web of Science ®Google Scholar
• Cui LH, Xu HR, Yang W, et al. lncRNA PCAT6 promotes non-small cell lung cancer cell proliferation, migration and invasion through regulating miR-330-5p. Onco Targets Ther. 2018;11:7715–7724.
   PubMed Web of Science ®Google Scholar
• Ma Z, Gu G, Pan W, et al. LncRNA PCAT6 accelerates the progression and chemoresistance of cervical cancer through up-regulating ZEB1 by sponging miR-543. Onco Targets Ther. 2020;13:1159–1170.
   PubMed Web of Science ®Google Scholar
• Wu H, Zou Q, He H, et al. Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med. 2019;8:2484–2495.
   PubMed Web of Science ®Google Scholar
• Cui Z, Liu Z, Zeng J, et al. TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells. Life Sci. 2019;224:23–32.
   PubMed Web of Science ®Google Scholar
• Hong Y, Liang H, Uzair Ur R, et al. miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 2016;6:37421.
   PubMed Web of Science ®Google Scholar
• Liu B, Wu S, Ma J, et al. lncRNA GAS5 reverses EMT and tumor stem cell-mediated gemcitabine resistance and metastasis by targeting miR-221/SOCS3 in pancreatic cancer. Mol Ther Nucleic Acids. 2018;13:472–482.
   PubMedGoogle Scholar
• Yang B, Diao H, Wang P, et al. microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1. Bioengineered. 2021;12(1):9094–9102.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cheng F, Rong G, et al. Circular RNA hsa_circ_0005567 overexpression promotes M2 type macrophage polarization through miR-492/SOCS2 axis to inhibit osteoarthritis progression. Bioengineered. 2021; 12:8920–8930.
   PubMed Web of Science ®Google Scholar
• Li Z, Yu Z, Meng X, et al. LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2. Biochem Biophys Res Commun. 2018;504:499–504.
   PubMed Web of Science ®Google Scholar
• Cai L, Ye L, Hu X, et al. MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4. Bioengineered. 2021;12:440–449.
   PubMed Web of Science ®Google Scholar
• Sun C, Huang C, Li S, et al. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget. 2016;7:8341–8359.
   PubMedGoogle Scholar
• Wu Y, Cheng K, Liang W, et al. lncRNA RPPH1 promotes non-small cell lung cancer progression through the miR-326/WNT2B axis. Oncol Lett. 2020;20:105.
   PubMed Web of Science ®Google Scholar
• Tan Q, Liu C, Shen Y, et al. Circular RNA circ_0000517 facilitates the growth and metastasis of non-small cell lung cancer by sponging miR-326/miR-330-5p. Cell J. 2021;23:552–561.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Hattori N, Ishikawa N, et al. Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer. Pathobiology. 2012;79:24–33.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Schoenfeld AJ, Zhu VW, et al. Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK inhibitors. J Thorac Oncol. 2020;15:258–265.
   PubMed Web of Science ®Google Scholar
• Hida T, Ogawa S, Park JC, et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009;9:17–35.
   PubMed Web of Science ®Google Scholar
• Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–2681.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Liu X, Lu X, Zhen F, et al. LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K/AKT pathway in NSCLC. Mol Ther Nucleic Acids. 2019;16:155–161.
   PubMedGoogle Scholar
• Wang L, Dong X, Ren Y, et al. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. 2018;9:129.
   PubMed Web of Science ®Google Scholar
• Chen ZY, Liu HY, Jiang N, et al. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621. Eur Rev Med Pharmacol Sci. 2019;23:9939–9946.
   PubMed Web of Science ®Google Scholar
• Xu T, Yan S, Wang M, et al. LncRNA UCA1 induces acquired resistance to gefitinib by epigenetically silencing CDKN1A expression in non-small-cell lung cancer. Front Oncol. 2020;10:656.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang X, Yang C, et al. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell Cycle. 2018;17:1772–1783.
   PubMed Web of Science ®Google Scholar
• Kong FR, Lv YH, Yao HM, et al. LncRNA PCAT6 promotes occurrence and development of ovarian cancer by inhibiting PTEN. Eur Rev Med Pharmacol Sci. 2019;23:8230–8238.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang Z, Tong F, et al. lncRNA UCA1 promotes gefitinib resistance as a ceRNA to target FOSL2 by sponging miR-143 in non-small cell lung cancer. Mol Ther Nucleic Acids. 2020;19:643–653.
   PubMedGoogle Scholar
• Ge P, Cao L, Zheng M, et al. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis. Exp Mol Pathol. 2021;120:104633.
   PubMed Web of Science ®Google Scholar
• Huang W, Yan Y, Liu Y, et al. Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1. Signal Transduct Target Ther. 2020;5:39.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Gao XH, Ma MY, et al. CircRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 axis. Sci Rep. 2020;10:9024.
   PubMed Web of Science ®Google Scholar
• Miao LJ, Huang SF, Sun ZT, et al. MiR-449c targets c-Myc and inhibits NSCLC cell progression. FEBS Lett. 2013;587:1359–1365.
   PubMed Web of Science ®Google Scholar
• Song W, Qian Y, Zhang MH, et al. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24:3049–3061.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zhang Y, Hao L, et al. CircRNA_102272 promotes cisplatin-resistance in hepatocellular carcinoma by decreasing MiR-326 targeting of RUNX2. Cancer Manag Res. 2020;12:12527–12534.
   PubMed Web of Science ®Google Scholar
• Booy S, Hofland LJ, Waaijers AM, et al. Type I interferon receptor expression in human pancreatic and periampullary cancer tissue. Pancreas. 2015;44:99–105.
   PubMed Web of Science ®Google Scholar
• Ota H, Nagano H, Doki Y, et al. Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers. Oncol Rep. 2006;16:249–255.
   PubMed Web of Science ®Google Scholar
• Ito K, Tanaka H, Ito T, et al. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur J Haematol. 2004;73:191–205.
   PubMed Web of Science ®Google Scholar
• Ariyasu T, Fujioka N, Yamamoto S, et al. Correlation between interferon alpha receptor protein expression and sensitivity to interferon alpha subtypes in human renal carcinoma cell lines. Cancer Genomics Proteomics. 2004;1:87–94.
   PubMedGoogle Scholar